WO2018111023A1 - Lactic acid bacteria having increased stability, and method for producing same - Google Patents
Lactic acid bacteria having increased stability, and method for producing same Download PDFInfo
- Publication number
- WO2018111023A1 WO2018111023A1 PCT/KR2017/014806 KR2017014806W WO2018111023A1 WO 2018111023 A1 WO2018111023 A1 WO 2018111023A1 KR 2017014806 W KR2017014806 W KR 2017014806W WO 2018111023 A1 WO2018111023 A1 WO 2018111023A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lactic acid
- acid bacteria
- cfu
- coating
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
Definitions
- the present invention relates to a lactic acid bacterium having improved stability and a method for preparing the same, more specifically xylitol; Gelatin or collagen; And the present invention relates to a lactic acid bacterium and a method for producing the same which is enhanced by storage and thermal stability, acid resistance, bile resistance, and digestive enzymes by triple coating of dextrin sequentially.
- Lactic acid bacteria also known as lactic acid bacteria or lactic acid bacteria, are gram-positive bacteria that break down sugars such as glucose to produce lactic acid. They are found in the digestive tract, oral cavity, and vagina of humans and mammals. Lactic acid bacteria are one of the most widely used microorganisms for a long time, and do not produce harmful substances to the intestines of humans or animals, and are useful as a formal preparation by preventing abnormal fermentation by harmful bacteria in the intestines. In addition, the lactic acid produced by the lactic acid fermentation has been used to produce foods such as dairy products, kimchi, brewed foods, etc., which inhibit the growth of pathogens and harmful bacteria.
- probiotics are living bacteria that enter the body and give a healthy effect.
- Most probiotics known to date are Lactobacillus sp . , Lactococcus sp . ), Streptococcus sp . , Leuconostoc sp . ), And O Phedi deulyimyeo lactic acid bacteria belonging to genus Lactococcus such as (Pedicoccus sp.), Includes a part of Bacillus (Bacillus) and the like.
- the function of lactic acid bacteria and probiotics has been studied for a long time since it was found by Ilya Mechinnikov that Bulgarians enjoy longevity due to the consumption of fermented milk fermented with Lactobacillus.
- probiotics are reported to be effective in preventing lactose intolerance and colon cancer, lowering cholesterol and blood pressure, improving immune function, preventing infection, improving mineral absorption, growing harmful bacteria due to stress, and improving irritable bowel syndrome and colitis. It has also been recommended as a treatment and antibiotic for strengthening the immune system and for treating intestinal diseases associated with candidiasis.
- microorganisms including lactic acid bacteria must survive in gastric acid and bile acids, reach the small intestine, proliferate and settle in the intestine, exhibit useful effects in the intestine, be nontoxic and non-pathogenic.
- Lactic acid bacteria food is made of powder, granules, tablets, capsules, etc. to cultivate live bacteria such as lactobacillus, lactobacillus, bifidus and other foods in a stable and easy way.
- Lactic acid bacteria production process as described above is largely divided into lactic acid bacteria culture, cell recovery, lyophilization, grinding, commercialization, etc.
- lactic acid bacteria are exposed to various physicochemical stresses.
- the cell recovery is affected by osmotic pressure due to concentration, and during freeze-drying process, ice crystals in the cytoplasm are formed due to rapid temperature change, or ice crystals and dehydration generated outside the cell affect the temperature and osmotic pressure.
- osmotic pressure due to concentration
- ice crystals in the cytoplasm are formed due to rapid temperature change, or ice crystals and dehydration generated outside the cell affect the temperature and osmotic pressure.
- lactic acid bacteria is reduced when exposed to high temperature, high pressure or hydrated by moisture in the air during grinding and commercialization, and liquid products such as lactic acid bacteria fermented foods, lactic acid bacteria fermented milk, lactic acid bacteria beverages stored for a short period of time, as well as long-term Even in products manufactured in powder form for the purpose of storage, it has been pointed out that when exposed to oxygen, the fatty acids constituting the cell membrane are oxidized to reduce the survival rate.
- probiotics products utilize the live bacteria themselves, they are exposed to various stresses in the human body before reaching the intestines after ingestion.
- the survival rate may be greatly reduced by being exposed to an acidic environment falling below pH 3 and affected by digestive enzymes and bile acids secreted in the small intestine. Even when it reaches the intestine, it competes with the microorganisms that have settled in the intestine, and at the same time, the growth is inhibited by various harmful components and active oxygen.
- a high concentration of lactic acid bacteria is introduced a method of producing a double-structured jelly or double coating with protein and polysaccharides, or direct reaction with air, water is suppressed and heat resistance, acid resistance and A method of preparing tri-coated lactic acid bacteria (BK Patent Application No. 10-2008-10397) with enhanced bile properties and enhanced viability and processing stability has been developed.
- the coating technique of the conventional lactic acid bacteria also can not completely coat the surface of the lactic acid bacteria, it is still pointed out that the lactic acid bacteria prepared by the above method is not sufficiently excellent in heat resistance, acid resistance and bile resistance.
- the present inventors earnestly researched to develop a method capable of improving the storage and lactic acid bacteria stability in the body, as a result, the lactic acid bacteria, preferably Lactobacillus pentosus strain Xylitol; Gelatin or collagen; And the result of the three-coating sequentially using the dextrin was confirmed that the storage stability, thermal stability, acid resistance, bile resistance, and the stability of the digestive enzymes of the strain is improved, the present invention was completed based on this.
- the lactic acid bacteria preferably Lactobacillus pentosus strain Xylitol
- Gelatin or collagen the result of the three-coating sequentially using the dextrin was confirmed that the storage stability, thermal stability, acid resistance, bile resistance, and the stability of the digestive enzymes of the strain is improved, the present invention was completed based on this.
- an object of the present invention is to provide a method for producing lactic acid bacteria with improved stability.
- the present invention provides a method for producing lactic acid bacteria with improved stability, including the following steps.
- the present invention provides a method for enhancing the stability of lactic acid bacteria, comprising the following steps.
- xylitol in the step (a) may be 1% to 30% concentration.
- the gelatin or collagen in step (b) may be 1% to 30% concentration.
- the dextrin in step (c) may be a concentration of 10% to 50%.
- the xylitol in the step (a), is mixed with the primary coating in a ratio of 10 parts by weight to 100 parts by weight with respect to 100 parts by weight of lactic acid bacteria cells;
- the gelatin or collagen is mixed with a secondary coating in a ratio of 0.5 parts by weight to 50 parts by weight with respect to 100 parts by weight of lactic acid bacteria cells;
- the dextrin may comprise a third coating by mixing in a ratio of 0.5 parts by weight to 50 parts by weight with respect to 100 parts by weight of lactic acid bacteria cells.
- the lactic acid bacteria is Lactobacillus sp. , Genus Bifidobacterium ( Bifidobacterium) sp . ), Genus Streptococcus sp. , Genus Lactococcus sp . ) Enterococcus sp . ), Pediococcus sp . , Genus Leuconostoc sp . ), And Weissella sp. ) May be one or more strains selected from the group consisting of.
- the lactic acid bacteria may be Lactobacillus pentosus .
- Lactic acid bacteria prepared by the coating method according to the present invention is xylitol; Gelatin or collagen; And triple-coating sequentially with dextrin, to experimentally confirm that the storage temperature and heat stability, acid resistance, bile resistance, and digestive enzyme stability are improved compared to lactic acid bacteria which have not been conventionally coated, thereby resisting external stress. And it was confirmed that the viability of the strain when passing through the gastrointestinal tract and can maintain the original physiological activity function in the intestine, the coating method according to the present invention is fermented milk, fermented food, functional food, general food, cosmetics, and using lactic acid bacteria It is expected to be usefully used in related industries such as pharmaceuticals.
- 1 is a photograph of the final raw material after freeze-drying the Lactobacillus pentosus KF340 strain sequentially coated with xylitol, gelatin, and dextrin triple.
- Figure 2 is a photograph of the final raw material after lyophilization of Lactobacillus pentosus KF340 strain sequentially coated with xylitol, collagen, and dextrin in threefold.
- Figure 3 is a photograph taken with a scanning electron microscope of the Lactobacillus pentosus KF340 strain sequentially coated with xylitol, gelatin, and dextrin triple.
- FIG. 4 is a photograph taken with a scanning electron microscope of the Lactobacillus pentosus KF340 strain sequentially coated with xylitol, collagen, and dextrin in a triple.
- the present inventors have studied diligently to develop a coating method that can enhance the storage and stability of the lactic acid bacteria in the body, and as a result, the storage and thermal stability of the strain, acid resistance, bile resistance, and lactic acid bacteria with enhanced stability to digestive enzymes
- the present invention has been completed by developing a coating method.
- the present invention (a) adding xylitol to the lactic acid bacteria and homogenizing the first coating; (b) adding a gelatin or collagen to the first coated lactic acid bacteria and homogenizing the second coating to homogenize; And (c) adding a dextrin (dextrin) to the secondary coated lactic acid bacteria and provides a method of producing a lactic acid bacteria with improved stability, comprising the step of homogeneous tertiary coating.
- the present invention (a) adding xylitol to the lactic acid bacteria and homogenizing the first coating; (b) adding a gelatin or collagen to the first coated lactic acid bacteria and homogenizing the second coating to homogenize; And (c) adding a dextrin to the secondary coated lactic acid bacteria and homogenizing the third coating to provide a method for enhancing stability of the lactic acid bacteria.
- the lactic acid bacteria culture can be carried out in conventional lactic acid culture medium and culture conditions according to the type of lactic acid bacteria to be used, and is not particularly limited.
- xylitol is dissolved in distilled water and may be in a concentration of 1% to 30%, preferably 1% to 15%, more preferably 3% to 7%, even more preferably 5%, and use. Pre-sterilized, cooled to room temperature and available for coating.
- the xylitol is added to 10 parts by weight to 100 parts by weight, preferably 50 parts by weight to 100 parts by weight, more preferably 100 parts by weight, which is the same amount as that of recovered cells, and homogenized, and room temperature.
- the cells can be first coated by standing at room temperature for 0.5 to 3 hours, more preferably 1 hour to 2 hours.
- gelatin may be dissolved in distilled water at a concentration of 1% to 30%, preferably 1% to 15%, more preferably 4% to 7%, even more preferably 6%, and used. Pre-sterilized, cooled to room temperature and available for coating.
- the gelatin is added to 0.5 parts by weight to 50 parts by weight, preferably 5 parts by weight to 50 parts by weight, more preferably 10 parts by weight to 30 parts by weight, based on 100 parts by weight of the cells recovered after the culture, and homogenized at room temperature.
- the cells can be secondary coated by standing at room temperature for 0.5 to 3 hours, more preferably 1 to 2 hours.
- the collagen may be dissolved in distilled water at a concentration of 1% to 30%, preferably 5% to 20%, more preferably 10% to 15%, even more preferably 12%, and used. Pre-sterilized, cooled to room temperature and available for coating.
- the collagen is homogenized after adding 0.5 parts by weight to 50 parts by weight, preferably 5 parts by weight to 50 parts by weight, more preferably 10 parts by weight to 30 parts by weight, based on 100 parts by weight of the cells recovered after the culture.
- the cells can be secondary coated by standing at room temperature for 0.5 to 3 hours, more preferably 1 to 2 hours.
- the dextrin may be dissolved in distilled water at a concentration of 10% to 50%, preferably 10% to 30%, more preferably 15% to 25%, even more preferably 20%, and used. Pre-sterilized, cooled to room temperature and available for coating.
- the dextrin is homogenized after adding 0.5 parts by weight to 50 parts by weight, preferably 5 parts by weight to 50 parts by weight, more preferably 10 parts by weight to 30 parts by weight, based on 100 parts by weight of the cells recovered after the culture.
- the cells may be tertiary coated by standing at room temperature for 0.5 to 3 hours, more preferably 1 to 2 hours.
- the present invention may include a process of lyophilizing the coated lactic acid bacteria after the lactic acid bacteria coating process as described above, it can be carried out by those skilled in the art according to a conventional method.
- the stability is meant to include both in vitro stability and in vivo stability to lactic acid bacteria, more specifically, storage and heat resistance to lactic acid bacteria, bile acid, acid resistance, and digestive enzymes Stability, and stability in intestinal conditions.
- the stability of the strain was evaluated in various aspects as compared to the case where the Lactobacillus pentosus strain was not coated after the triple coating by the above production method.
- the viable cell count and viability were measured at two-week intervals while storing the lactic acid bacteria samples for 4 weeks at 4, 25, and 40 ° C. conditions to evaluate storage stability enhancement.
- the rate of decrease of the cells increases, and it was confirmed that the survival rate of the tri-coated lactic acid bacteria was significantly increased as compared with the case without the coating treatment (see Example 3).
- the lactic acid bacteria samples were treated with artificial gastric juice of pH 2.0 and 2.5, respectively, and reacted for 30 minutes, 60 minutes, and 120 minutes, and then the viable cell count and survival rate. Measured. As a result, it was found that the survival rate was higher in the triple coated sample according to the present invention compared to the case where the coating was not performed (see Example 4).
- the lactic acid bacteria were treated with 0.2% pancreatin and 100 unit / mL of alpha-amylase, respectively, for 30 minutes, 60 minutes, and to evaluate the stability of the lactic acid bacteria for digestive enzymes. After reacting for 120 minutes, viable cell count and viability were measured. As a result, it was possible to confirm the high digestive enzyme stability of the Lactobacillus pentosus strain itself used in this example, it was confirmed that the stability of the digestive enzymes of the lactic acid bacteria by the triple coating treatment according to the present invention is more enhanced. (See Example 6).
- the triple coating method according to the present invention generally improves the storage stability, acid resistance, bile resistance, stability against digestive enzymes, and thermal stability according to storage temperature, compared to the non-coated lactic acid bacteria.
- the triple coating method according to the present invention generally improves the storage stability, acid resistance, bile resistance, stability against digestive enzymes, and thermal stability according to storage temperature, compared to the non-coated lactic acid bacteria.
- the present invention provides a tri-coated lactic acid bacteria prepared by the above method.
- the lactic acid bacteria are Lactobacillus bacteria (Lactobacillus sp.) Genus, Bifidobacterium (Bifidobacterium sp.), A Streptococcus (Streptococcus sp.) Genus Lactococcus (Lactococcus sp.) Genus Enterococcus (Enterococcus sp . ), Pediococcus sp . , Genus Leuconostoc sp . ), And Weissella sp.
- Genus may be one or more strains selected from the group consisting of, more preferably Lactobacillus pentosus ( Lactobacillus pentosus ), more preferably Lactobacillus pentosus KF340 (Accession number KCCM 11675P).
- Lactobacillus pentosus KF340 strain was incubated with stirring for 12 ⁇ 3 hours at 32 °C, pH 6.0 conditions using 360 L modified-MRS medium.
- the cultured Lactobacillus pentosus KF340 cells were separated using a centrifuge, and 5.2 Kg of cells were recovered through this process.
- Experimental group 1 is a triple coating strain using xylitol, gelatin, and dextrin
- experimental group 2 is a triple coating strain using xylitol, collagen, and dextrin
- the control group is an uncoated strain.
- Experimental Group 1 dissolved each raw material in distilled water so as to have a concentration of 5% xylitol, 6% gelatin, and 20% dextrin. Sterilized at 121 ° C. for 15 minutes and then cooled at room temperature. Next, the same amount of 5% xylitol aqueous solution was added to the recovered cells, and the cells were homogenized and allowed to stand for 1 hour to be first coated.
- the mixture After adding 12% collagen aqueous solution to 25% of the recovered cells and homogenizing the cells, the mixture was left to stand for 1 hour and then coated with 20% dextrin solution to 25% of the recovered cells. After homogenization, the mixture was allowed to stand for 1 hour and subjected to tertiary coating. In this case, the same cells without coating treatment were used as the control (sample 3) without any raw material.
- the samples of Table 1 were prepared according to the method of Example 2, and then 4 weeks at 4, 25, and 40 ° C., respectively.
- the viable cell counts were measured at two week intervals during storage.
- the cells stored at each storage temperature were suspended in sterile saline solution, aliquoted and smeared according to dilution ratio in MRS (Difco) solid medium, and then cultured for 48 hours at 37 ° C. to measure colony numbers. .
- the survival rate (%) is expressed as [(Log index value at Week 4 / Log index value at Week 0) X 100].
- Experiment group 1 Control Week 0 4.6 X 10 8 (CFU / mg) 2.8 X 10 8 (CFU / mg) 1.2 X 10 8 (CFU / mg) 2 weeks 2.0 X 10 8 (CFU / mg) 2.4 X 10 8 (CFU / mg) 2.5 X 10 7 (CFU / mg) 4 Weeks 2.0 X 10 8 (CFU / mg) 2.2 X 10 8 (CFU / mg) 3.1 X 10 7 (CFU / mg) Survival Rate after Week 4 (%) 95.8 (%) 98.8 (%) 92.6 (%)
- Experiment group 1 Experiment group 2 Control Week 0 4.6 X 10 8 (CFU / mg) 2.8 X 10 8 (CFU / mg) 1.2 X 10 8 (CFU / mg) 2 weeks 8.3 X 10 7 (CFU / mg) 9.3 X 10 7 (CFU / mg) 1.3 X 10 6 (CFU / mg) 4 Weeks 8.9 X 10 7 (CFU / mg) 5.0 X 10 7 (CFU / mg) 5.1 X 10 6 (CFU / mg) Survival Rate after Week 4 (%) 91.8 (%) 91.2 (%) 82.9 (%)
- Experiment group 1 Experiment group 2 Control Week 0 4.6 X 10 8 (CFU / mg) 2.8 X 10 8 (CFU / mg) 1.2 X 10 8 (CFU / mg) 2 weeks 1.6 X 10 7 (CFU / mg) 1.5 X 10 7 (CFU / mg) 1.7 X 10 3 (CFU / mg) 4 Weeks 4.5 X 10 6 (CFU / mg) 1.2 X 10 7 (CFU / mg) 4.5 X 10 3 (CFU / mg) Survival Rate after Week 4 (%) 76.8 (%) 83.9 (%) 45.1 (%)
- the samples of Table 1 were prepared according to the method of Example 2 and then added with artificial gastric juice of pH 2.0 and 2.5, respectively, for 30 minutes, After reacting for 60 minutes and 120 minutes, the solution was diluted 10-fold with sterile saline solution and dispensed and plated according to the dilution ratio in MRS (Difco) solid medium. Thereafter, the colonies were measured by incubating at 37 ° C. for 48 hours, and the survival rate (%) was expressed as [(Log index value after initial gastric fluid exposure / initial Log index value) ⁇ 100].
- the survival rate of the cells showed a tendency to decrease as the time of exposure to gastric juice (pH solution) increased, and coating treatment was performed at both pH 2.0 and pH 2.5 conditions. Compared with the control group did not show a high survival rate in the three-coated experiment groups 1 and 2. In addition, it was confirmed that the triple coating method significantly increased acid resistance compared to the case where no treatment was observed when maintaining a survival rate of about 95% or more in an acidic environment of 98% or more and pH 2.0 in a pH 2.5 condition.
- Experiment group 1 Control 0 min 2.0 X 10 8 (CFU / mg) 2.1 X 10 8 (CFU / mg) 1.7 X 10 7 (CFU / mg) 30 minutes 2.8 X 10 8 (CFU / mg) 9.4 X 10 7 (CFU / mg) 2.1 X 10 7 (CFU / mg) 60 minutes 1.0 X 10 8 (CFU / mg) 1.1 X 10 8 (CFU / mg) 6.1 X 10 6 (CFU / mg) 120 minutes 7.9 X 10 7 (CFU / mg) 7.4 X 10 7 (CFU / mg) 4.8 X 10 6 (CFU / mg) Survival rate after 120 minutes (%) 95.0 (%) 94.5 (%) 92.5 (%)
- Experiment group 1 Control 0 min 2.0 X 10 8 (CFU / mg) 2.1 X 10 8 (CFU / mg) 1.4 X 10 7 (CFU / mg) 30 minutes 2.3 X 10 8 (CFU / mg) 1.7 X 10 8 (CFU / mg) 1.4 X 10 7 (CFU / mg) 60 minutes 2.2 X 10 8 (CFU / mg) 1.7 X 10 8 (CFU / mg) 1.5 X 10 7 (CFU / mg) 120 minutes 1.6 X 10 8 (CFU / mg) 1.6 X 10 8 (CFU / mg) 6.7 X 10 6 (CFU / mg) Survival rate after 120 minutes (%) 98.8 (%) 98.4 (%) 94.4 (%)
- the samples of Table 1 were prepared according to the method of Example 2 and then bile solution (Bile extract 0.3%, 2.0%) The reaction was carried out for 30 minutes, 60 minutes and 120 minutes, and then diluted 10-fold with sterile saline, and then dispensed and plated according to the dilution ratio in MRS (Difco) solid medium. After culturing at 37 ° C. for 48 hours to determine colony numbers, the survival rate (%) was expressed as [(Log index value after initial bile acid exposure / initial Log index value) ⁇ 100].
- Experiment group 1 Control 0 min 1.9 X 10 8 (CFU / mg) 1.4 X 10 8 (CFU / mg) 3.1 X 10 7 (CFU / mg) 30 minutes 2.9 X 10 7 (CFU / mg) 3.6 X 10 7 (CFU / mg) 3.0 X 10 6 (CFU / mg) 60 minutes 3.3 X 10 7 (CFU / mg) 3.8 X 10 7 (CFU / mg) 5.8 X 10 6 (CFU / mg) 120 minutes 6.3 X 10 7 (CFU / mg) 3.7 X 10 7 (CFU / mg) 2.6 X 10 6 (CFU / mg) Survival rate after 120 minutes (%) 94.3 (%) 92.8 (%) 85.7 (%)
- Experiment group 1 Control 0 min 1.9 X 10 8 (CFU / mg) 1.4 X 10 8 (CFU / mg) 3.1 X 10 7 (CFU / mg) 30 minutes 2.3 X 10 7 (CFU / mg) 2.7 X 10 7 (CFU / mg) 4.0 X 10 6 (CFU / mg) 60 minutes 2.6 X 10 7 (CFU / mg) 3.1 X 10 7 (CFU / mg) 2.4 X 10 6 (CFU / mg) 120 minutes 4.1 X 10 7 (CFU / mg) 5.0 X 10 7 (CFU / mg) 3.3 X 10 6 (CFU / mg) Survival rate after 120 minutes (%) 92.0 (%) 94.4 (%) 87.1 (%)
- the samples of Table 1 were prepared according to the method of Example 2 after digestion enzyme solution, that is, 0.2% pancreatin (pancreatin) and 100 unit / mL of alpha-amylase were added, respectively, and reacted for 30 minutes, 60 minutes, and 120 minutes, and then diluted 10-fold with sterile saline solution to dilute the MRS (Difco) solid medium. Dispensed and smeared accordingly. Colonies were measured after incubation at 37 ° C. for 48 hours. The survival rate (%) was expressed as [(Log index value / initial Log index value after digestive enzyme solution exposure) ⁇ 100].
- Experiment group 1 Control 0 min 2.2 X 10 8 (CFU / mg) 1.2 X 10 8 (CFU / mg) 2.8 X 10 7 (CFU / mg) 30 minutes 3.0 X 10 8 (CFU / mg) 2.2 X 10 8 (CFU / mg) 2.7 X 10 7 (CFU / mg) 60 minutes 3.5 X 10 8 (CFU / mg) 2.4 X 10 8 (CFU / mg) 3.2 X 10 7 (CFU / mg) 120 minutes 2.4 X 10 8 (CFU / mg) 2.0 X 10 8 (CFU / mg) 1.1 X 10 7 (CFU / mg) Survival rate after 120 minutes (%) 100.4 (%) 102.6 (%) 94.8 (%)
- Experiment group 1 Control 0 min 1.5 X 10 8 (CFU / mg) 1.5 X 10 8 (CFU / mg) 2.2 X 10 7 (CFU / mg) 30 minutes 3.3 X 10 8 (CFU / mg) 2.4 X 10 8 (CFU / mg) 1.5 X 10 7 (CFU / mg) 60 minutes 3.6 X 10 8 (CFU / mg) 2.5 X 10 8 (CFU / mg) 2.1 X 10 7 (CFU / mg) 120 minutes 2.9 X 10 8 (CFU / mg) 3.1 X 10 8 (CFU / mg) 1.5 X 10 7 (CFU / mg) Survival rate after 120 minutes (%) 103.4 (%) 104.1 (%) 97.9 (%)
- the samples of Table 1 were prepared according to the method of Example 2 and then the temperature at 40 °C, 50 °C, and 70 °C Sterile saline solution was added to each sample and maintained at the same temperature for 10 minutes and 30 minutes in a constant temperature bath, and then diluted 10 times with sterile saline solution and dispensed and plated according to the dilution ratio in MRS (Difco) solid medium. After 48 hours of incubation at 37 °C colony number was measured, the survival rate (%) is expressed as [(Log index value / initial Log index value after heat treatment) X 100].
- the difference in thermal stability by coating treatment was more prominent at 70 °C high temperature condition, whereas the control group without coating was not identified after living treatment for 30 minutes.
- the experimental group 2 which is greatly improved to the above and triple-coated, has great significance in that the cell survival rate is improved to 20% or more. Therefore, in view of the previous results, the triple-coated sample of Lactobacillus pentosus KF340 protects the strain from the external environment, thereby increasing the storage stability, acid resistance, bile resistance, stability of digestive enzymes, and thermal stability according to storage temperature. It was found to improve.
- Experiment group 1 Control 0 min 1.4 X 10 8 (CFU / mg) 1.4 X 10 8 (CFU / mg) 1.9 X 10 7 (CFU / mg) 10 minutes 2.4 X 10 8 (CFU / mg) 2.1 X 10 8 (CFU / mg) 1.2 X 10 7 (CFU / mg) 30 minutes 2.2 X 10 8 (CFU / mg) 1.7 X 10 8 (CFU / mg) 1.0 X 10 7 (CFU / mg) Survival rate after 30 minutes (%) 102.4 (%) 101.2 (%) 96.4 (%)
- Experiment group 1 Control 0 min 1.4 X 10 8 (CFU / mg) 1.4 X 10 8 (CFU / mg) 1.9 X 10 7 (CFU / mg) 10 minutes 4.8 X 10 7 (CFU / mg) 4.2 X 10 7 (CFU / mg) 3.6 X 10 6 (CFU / mg) 30 minutes 2.8 X 10 7 (CFU / mg) 2.2 X 10 7 (CFU / mg) 1.6 X 10 6 (CFU / mg) Survival rate after 30 minutes (%) 91.4 (%) 90.3 (%) 85.1 (%)
- Experiment group 1 Control 0 min 2.1 X 10 8 (CFU / mg) 2.1 X 10 8 (CFU / mg) 1.1 X 10 7 (CFU / mg) 10 minutes 4.3 X 10 4 (CFU / mg) 9.0 X 10 4 (CFU / mg) 7.3 X 10 3 (CFU / mg) 30 minutes 5.5 X 10 2 (CFU / mg) 5.0 X 10 1 (CFU / mg) - Survival rate after 30 minutes (%) 33.0 (%) 20.4 (%) 0.0 (%)
- the present invention is xylitol; Gelatin or collagen; And by sequentially coating the lactic acid bacteria with dextrin in triplicate, it was experimentally confirmed that the stability to storage temperature and heat, acid resistance, bile resistance, and digestive enzymes were improved more than lactic acid bacteria which were not conventionally coated.
- the present invention can be maintained in the intestinal physiological activity through the gastrointestinal tract without killing the lactic acid bacteria enhanced stability by triple coating, fermented milk, fermented foods, functional foods, general foods, cosmetics, and pharmaceuticals It is expected to be usefully used in related industries.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Birds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 안정성이 증진된 유산균 및 이의 제조방법에 관한 것으로, 보다 구체적으로는 자일리톨; 젤라틴 또는 콜라겐; 및 덱스트린을 순차적으로 3중 코팅함으로써 저장 및 열안정성, 내산성, 내담즙성, 및 소화효소에 대한 안정성이 증진된 유산균 및 이의 제조방법에 관한 것이다.The present invention relates to a lactic acid bacterium having improved stability and a method for preparing the same, more specifically xylitol; Gelatin or collagen; And the present invention relates to a lactic acid bacterium and a method for producing the same which is enhanced by storage and thermal stability, acid resistance, bile resistance, and digestive enzymes by triple coating of dextrin sequentially.
유산균(lactic acid bacteria)은 락트산 균 또는 젖산균이라고도 하며, 글루코오스 등의 당류를 분해하여 젖산을 생성하는 그람 양성세균으로, 사람이나 포유동물의 소화관, 구강, 및 질 등에서 발견된다. 유산균은 인류가 가장 오랫동안 광범위하게 활용하고 있는 미생물 중 하나로서, 사람이나 동물의 장에 해로운 물질을 생성하지 않으며 장내에서 유해균에 의한 이상발효를 방지해 정장제로도 유용하게 이용되고 있다. 또한, 젖산발효에 의해 생성되는 젖산에 의해서 병원균과 유해균의 생육이 저지되는 성질을 유제품, 김치류, 양조식품 등의 식품 제조에도 이용해왔다.Lactic acid bacteria, also known as lactic acid bacteria or lactic acid bacteria, are gram-positive bacteria that break down sugars such as glucose to produce lactic acid. They are found in the digestive tract, oral cavity, and vagina of humans and mammals. Lactic acid bacteria are one of the most widely used microorganisms for a long time, and do not produce harmful substances to the intestines of humans or animals, and are useful as a formal preparation by preventing abnormal fermentation by harmful bacteria in the intestines. In addition, the lactic acid produced by the lactic acid fermentation has been used to produce foods such as dairy products, kimchi, brewed foods, etc., which inhibit the growth of pathogens and harmful bacteria.
한편, 프로바이오틱스(Probiotics)란 체내에 들어가서 건강에 좋은 효과를 주는 살아있는 균을 말한다. 현재까지 알려진 대부분의 프로바이오틱스는 락토바실러스 속(Lactobacillus sp .), 락토코커스 속(Lactococcus sp .), 스트렙토코커스 속(Streptococcus sp .), 류코노스톡 속(Leuconostoc sp .), 및 페디오코커스 속(Pedicoccus sp .) 등에 속하는 유산균들이며 일부 바실러스(Bacillus) 등을 포함하고 있다. 일리야 메치니코프에 의해 불가리아 사람들이 장수를 누리는 이유가 락토바실러스로 발효된 발효유의 섭취 때문이라는 것이 밝혀진 이래로 유산균, 프로바이오틱스의 기능성은 오랫동안 연구되어 오고 있다.On the other hand, probiotics are living bacteria that enter the body and give a healthy effect. Most probiotics known to date are Lactobacillus sp . , Lactococcus sp . ), Streptococcus sp . , Leuconostoc sp . ), And O Phedi deulyimyeo lactic acid bacteria belonging to genus Lactococcus such as (Pedicoccus sp.), Includes a part of Bacillus (Bacillus) and the like. The function of lactic acid bacteria and probiotics has been studied for a long time since it was found by Ilya Mechinnikov that Bulgarians enjoy longevity due to the consumption of fermented milk fermented with Lactobacillus.
임상적으로 프로바이오틱스는 유당불내증 및 결장암 예방, 콜레스테롤 및 혈압 저하, 면역기능 개선, 감염예방, 무기물의 흡수개량, 스트레스로 인한 유해한 세균의 성장 방지, 및 과민성대장증후군과 결장염 개선 등의 효과가 있다고 보고되어 있고, 또한, 면역시스템을 강하게 하며, 캔디다증과 관련된 장 질환 치료와 항생제로서 권고되어 왔다. 상기와 같은 유산균을 비롯한 미생물들이 프로바이오틱스로 인정받기 위해서는 위산과 담즙산에서 살아남아 소장까지 도달하여 장에서 증식하고 정착하여야 하며 장관 내에서 유용한 효과를 나타내어야 하고 독성이 없으며 비병원성이어야 한다.Clinically, probiotics are reported to be effective in preventing lactose intolerance and colon cancer, lowering cholesterol and blood pressure, improving immune function, preventing infection, improving mineral absorption, growing harmful bacteria due to stress, and improving irritable bowel syndrome and colitis. It has also been recommended as a treatment and antibiotic for strengthening the immune system and for treating intestinal diseases associated with candidiasis. In order to be recognized as probiotics, microorganisms including lactic acid bacteria must survive in gastric acid and bile acids, reach the small intestine, proliferate and settle in the intestine, exhibit useful effects in the intestine, be nontoxic and non-pathogenic.
유산균 식품은 유산간균, 유산구균, 비피더스균 등의 생균을 배양하여 식품에 혼합한 것을 안정적이고 섭취가 용이하도록 분말, 과립, 정제, 캡슐 등으로 만든 것으로 유산균 발효식품, 유산균 발효유, 유산균 음료 이외의 것을 말한다. 상기와 같은 유산균 식품을 제조하는 공정은 크게 유산균 배양, 균체 회수, 동결건조, 분쇄, 제품화 등으로 구분되는데 이 과정에서 유산균은 다양한 물리화학적인 스트레스에 노출된다. 즉, 균체회수 시에는 농축에 따른 삼투압 영향을 받으며, 동결건조 과정에서는 급격한 온도 변화에 따른 세포질 내 얼음결정이 형성되거나 세포 외부에 생성되는 얼음 결정 및 탈수(dehydration) 현상으로 인하여 온도와 삼투압 영향을 동시에 받게 된다. 또한, 분쇄 및 제품화 과정에서 고온, 고압에 노출되거나 공기 중의 수분에 의하여 수화(hydration)될 경우 유산균의 안정성이 떨어지게 되며, 단기간 보관되는 유산균 발효식품, 유산균 발효유, 유산균 음료와 같은 액상 제품뿐만 아니라 장기 보관을 목적으로 분말 형태로 제조되는 제품에 있어서도 산소에 노출될 경우 세포막을 구성하고 있는 지방산이 산화되어 생존율이 감소하게 되는 문제점이 지적되어 왔다.Lactic acid bacteria food is made of powder, granules, tablets, capsules, etc. to cultivate live bacteria such as lactobacillus, lactobacillus, bifidus and other foods in a stable and easy way. Say that. Lactic acid bacteria production process as described above is largely divided into lactic acid bacteria culture, cell recovery, lyophilization, grinding, commercialization, etc. In this process, lactic acid bacteria are exposed to various physicochemical stresses. In other words, the cell recovery is affected by osmotic pressure due to concentration, and during freeze-drying process, ice crystals in the cytoplasm are formed due to rapid temperature change, or ice crystals and dehydration generated outside the cell affect the temperature and osmotic pressure. At the same time. In addition, the stability of lactic acid bacteria is reduced when exposed to high temperature, high pressure or hydrated by moisture in the air during grinding and commercialization, and liquid products such as lactic acid bacteria fermented foods, lactic acid bacteria fermented milk, lactic acid bacteria beverages stored for a short period of time, as well as long-term Even in products manufactured in powder form for the purpose of storage, it has been pointed out that when exposed to oxygen, the fatty acids constituting the cell membrane are oxidized to reduce the survival rate.
또한, 프로바이오틱스 제품은 생균 자체를 이용하기 때문에 섭취 후 장에 도달하기 전에 인체 내에서 다양한 스트레스에 노출된다. 예컨대, 위장에서는 pH 3 이하로 떨어지는 산성 환경에 노출되고 소장에서는 분비되는 소화효소와 담즙산 등의 영향을 받아 생존율이 크게 감소할 수 있다. 장에 도달해서도 기존 장내 정착한 미생물과 경쟁함과 동시에 각종 유해 성분과 활성산소 등에 의한 성장 저해를 받게 된다.In addition, because probiotics products utilize the live bacteria themselves, they are exposed to various stresses in the human body before reaching the intestines after ingestion. For example, in the gastrointestinal tract, the survival rate may be greatly reduced by being exposed to an acidic environment falling below pH 3 and affected by digestive enzymes and bile acids secreted in the small intestine. Even when it reaches the intestine, it competes with the microorganisms that have settled in the intestine, and at the same time, the growth is inhibited by various harmful components and active oxygen.
최근까지 상기와 같은 문제점들을 해결하기 위하여, 유산균을 코팅하는 방법에 대한 다양한 연구들이 이루어져 왔다. 예컨대, 캡슐제를 이용한 장용코팅제와 젤라틴, 당류, 검류 등을 이용한 마이크로캡슐화(microencapsulation) 공정 등이 있었으나, 고가의 코팅제를 사용하거나 공정이 추가되는 문제점들이 지적되어 왔다.Until recently, in order to solve the above problems, various studies have been made on the method of coating lactic acid bacteria. For example, there have been enteric coatings using capsules and microencapsulation processes using gelatin, sugars, gums, etc., but problems of using expensive coatings or adding processes have been pointed out.
상기와 같은 문제점을 해결하기 위하여, 고농도의 유산균이 살아있는 이중 구조의 젤리를 제조하는 방법 또는 단백질과 다당류로 이중 코팅하는 방법을 도입하거나, 공기, 수분과의 직접적인 반응이 억제되며 내열성, 내산성 및 내담즙성이 강화되어 생균 안정성 및 가공 안정성이 증강된 3중 코팅 유산균의 제조방법(대한민국 특허출원 제10-2008-10397호)이 개발되었다. 그러나 상기의 종래 유산균의 코팅 기술 또한 유산균의 표면을 완전히 코팅할 수 없어, 상기의 방법으로 제조된 유산균은 내열성, 내산성 및 내담즙성이 충분히 우수하지 못한 문제점이 여전히 지적되었다. In order to solve the above problems, a high concentration of lactic acid bacteria is introduced a method of producing a double-structured jelly or double coating with protein and polysaccharides, or direct reaction with air, water is suppressed and heat resistance, acid resistance and A method of preparing tri-coated lactic acid bacteria (BK Patent Application No. 10-2008-10397) with enhanced bile properties and enhanced viability and processing stability has been developed. However, the coating technique of the conventional lactic acid bacteria also can not completely coat the surface of the lactic acid bacteria, it is still pointed out that the lactic acid bacteria prepared by the above method is not sufficiently excellent in heat resistance, acid resistance and bile resistance.
따라서 유산균이 체내에서 기능을 충분히 발휘하도록 저장안정성, 내열성, 내산성, 내담즙성 등을 현저히 증진시킬 수 있는 코팅방법의 개발이 필요하다.Therefore, it is necessary to develop a coating method that can significantly improve storage stability, heat resistance, acid resistance, and bile resistance so that lactic acid bacteria can fully function in the body.
본 발명자들은 유산균의 보관 및 체내에서의 안정성을 증진시킬 수 있는 방법을 개발하기 위하여 예의 연구한 결과, 상기 유산균, 바람직하게는 락토바실러스 펜토서스 균주를 자일리톨; 젤라틴 또는 콜라겐; 및 덱스트린을 이용해 순차적으로 3중 코팅한 결과 균주의 저장안정성, 열안정성, 내산성, 내담즙성, 및 소화효소에 대한 안정성이 증진되는 것을 확인하였는바, 이에 기초하여 본 발명을 완성하였다.The present inventors earnestly researched to develop a method capable of improving the storage and lactic acid bacteria stability in the body, as a result, the lactic acid bacteria, preferably Lactobacillus pentosus strain Xylitol; Gelatin or collagen; And the result of the three-coating sequentially using the dextrin was confirmed that the storage stability, thermal stability, acid resistance, bile resistance, and the stability of the digestive enzymes of the strain is improved, the present invention was completed based on this.
이에, 본 발명은 안정성이 증진된 유산균의 제조방법을 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide a method for producing lactic acid bacteria with improved stability.
또한, 본 발명은 유산균의 안정성 증진 방법을 제공하는 것을 다른 목적으로 한다. It is another object of the present invention to provide a method for enhancing the stability of lactic acid bacteria.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당해 기술분야의 통상의 기술자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problem, another task that is not mentioned will be clearly understood by those skilled in the art from the following description.
상기와 같은 본 발명의 목적을 달성하기 위하여, 본 발명은 하기의 단계를 포함하는, 안정성이 증진된 유산균의 제조방법을 제공한다.In order to achieve the object of the present invention as described above, the present invention provides a method for producing lactic acid bacteria with improved stability, including the following steps.
(a) 유산균에 자일리톨(xylitol)을 첨가하고 균질화 하여 1차 코팅하는 단계; (b) 상기 1차 코팅된 유산균에 젤라틴(gelatin) 또는 콜라겐(collagen)을 첨가하고 균질화 하여 2차 코팅하는 단계; 및 (c) 상기 2차 코팅된 유산균에 덱스트린(dextrin)을 첨가하고 균질화 하여 3차 코팅하는 단계.(a) adding a xylitol to the lactic acid bacteria and homogenizing the first coating; (b) adding a gelatin or collagen to the first coated lactic acid bacteria and homogenizing the second coating to homogenize; And (c) adding a dextrin to the second coated lactic acid bacterium and homogenizing the third coating.
또한, 본 발명은 하기의 단계를 포함하는, 유산균의 안정성 증진 방법을 제공한다.In addition, the present invention provides a method for enhancing the stability of lactic acid bacteria, comprising the following steps.
(a) 유산균에 자일리톨(xylitol)을 첨가하고 균질화 하여 1차 코팅하는 단계; (b) 상기 1차 코팅된 유산균에 젤라틴(gelatin) 또는 콜라겐(collagen)을 첨가하고 균질화 하여 2차 코팅하는 단계; 및 (c) 상기 2차 코팅된 유산균에 덱스트린(dextrin)을 첨가하고 균질화 하여 3차 코팅하는 단계. (a) adding a xylitol to the lactic acid bacteria and homogenizing the first coating; (b) adding a gelatin or collagen to the first coated lactic acid bacteria and homogenizing the second coating to homogenize; And (c) adding a dextrin to the second coated lactic acid bacterium and homogenizing the third coating.
본 발명의 일구현예로, 상기 (a) 단계에서 자일리톨은 1% 내지 30% 농도일 수 있다.In one embodiment of the present invention, xylitol in the step (a) may be 1% to 30% concentration.
본 발명의 다른 구현예로, 상기 (b) 단계에서 젤라틴 또는 콜라겐은 1% 내지 30% 농도일 수 있다. In another embodiment of the present invention, the gelatin or collagen in step (b) may be 1% to 30% concentration.
본 발명의 또 다른 구현예로, 상기 (c) 단계에서 덱스트린은 10% 내지 50% 농도일 수 있다. In another embodiment of the present invention, the dextrin in step (c) may be a concentration of 10% to 50%.
본 발명의 또 다른 구현예로, 상기 (a) 단계에서 상기 자일리톨은 유산균 균체 100 중량부 대비 10 중량부 내지 100 중량부의 비율로 혼합하여 1차 코팅하는 단계; 상기 (b) 단계에서 상기 젤라틴 또는 콜라겐은 유산균 균체 100 중량부 대비 0.5 중량부 내지 50 중량부의 비율로 혼합하여 2차 코팅하는 단계; 및 상기 (c) 단계에서 상기 덱스트린은 유산균 균체 100 중량부 대비 0.5 중량부 내지 50 중량부의 비율로 혼합하여 3차 코팅하는 단계를 포함할 수 있다.In another embodiment of the present invention, in the step (a), the xylitol is mixed with the primary coating in a ratio of 10 parts by weight to 100 parts by weight with respect to 100 parts by weight of lactic acid bacteria cells; In the step (b), the gelatin or collagen is mixed with a secondary coating in a ratio of 0.5 parts by weight to 50 parts by weight with respect to 100 parts by weight of lactic acid bacteria cells; And in the step (c) the dextrin may comprise a third coating by mixing in a ratio of 0.5 parts by weight to 50 parts by weight with respect to 100 parts by weight of lactic acid bacteria cells.
본 발명의 또 다른 구현예로, 상기 유산균은 락토바실러스(Lactobacillus sp.) 속, 비피도박테리움(Bifidobacterium sp .) 속, 스트렙토코커스(Streptococcus sp.) 속, 락토코커스(Lactococcus sp .) 속, 엔테로코커스(Enterococcus sp .) 속, 페디오코커스(Pediococcus sp .) 속, 류코노스톡(Leuconostoc sp .) 속, 및 비셀라(Weissella sp.) 속으로 이루어진 군에서 선택되는 하나 이상의 균주일 수 있다. In another embodiment of the present invention, the lactic acid bacteria is Lactobacillus sp. , Genus Bifidobacterium ( Bifidobacterium) sp . ), Genus Streptococcus sp. , Genus Lactococcus sp . ) Enterococcus sp . ), Pediococcus sp . , Genus Leuconostoc sp . ), And Weissella sp. ) May be one or more strains selected from the group consisting of.
본 발명의 또 다른 구현예로, 상기 유산균은 락토바실러스 펜토서스(Lactobacillus pentosus)일 수 있다.In another embodiment of the present invention, the lactic acid bacteria may be Lactobacillus pentosus .
본 발명에 따른 코팅방법으로 제조된 유산균은 자일리톨; 젤라틴 또는 콜라겐; 및 덱스트린을 이용해 순차적으로 3중 코팅함으로써 종래 코팅처리하지 않은 유산균에 비하여 보관온도 및 열에 대한 안정성, 내산성, 내담즙성, 및 소화효소에 대한 안정성이 증진되는 것을 실험적으로 확인함으로써 외부 스트레스에 대한 저항성 및 위장관 통과 시 균주의 생존력이 증가하고 장내에서 본래의 생리활성 기능을 유지할 수 있음을 확인하였는바, 본 발명에 따른 코팅 방법은 유산균을 이용한 발효유, 발효식품, 기능성 식품, 일반식품, 화장품, 및 의약품 등의 관련 산업에서 유용하게 이용될 수 있을 것으로 기대된다.Lactic acid bacteria prepared by the coating method according to the present invention is xylitol; Gelatin or collagen; And triple-coating sequentially with dextrin, to experimentally confirm that the storage temperature and heat stability, acid resistance, bile resistance, and digestive enzyme stability are improved compared to lactic acid bacteria which have not been conventionally coated, thereby resisting external stress. And it was confirmed that the viability of the strain when passing through the gastrointestinal tract and can maintain the original physiological activity function in the intestine, the coating method according to the present invention is fermented milk, fermented food, functional food, general food, cosmetics, and using lactic acid bacteria It is expected to be usefully used in related industries such as pharmaceuticals.
도 1은 자일리톨, 젤라틴, 및 덱스트린을 순차적으로 3중 코팅한 락토바실러스 펜토서스 KF340 균주를 동결건조한 후 최종 원료를 촬영한 사진이다.1 is a photograph of the final raw material after freeze-drying the Lactobacillus pentosus KF340 strain sequentially coated with xylitol, gelatin, and dextrin triple.
도 2는 자일리톨, 콜라겐, 및 덱스트린을 순차적으로 3중 코팅한 락토바실러스 펜토서스 KF340 균주를 동결건조한 후 최종 원료를 촬영한 사진이다.Figure 2 is a photograph of the final raw material after lyophilization of Lactobacillus pentosus KF340 strain sequentially coated with xylitol, collagen, and dextrin in threefold.
도 3은 자일리톨, 젤라틴, 및 덱스트린을 순차적으로 3중 코팅한 락토바실러스 펜토서스 KF340 균주를 주사전자현미경으로 촬영한 사진이다.Figure 3 is a photograph taken with a scanning electron microscope of the Lactobacillus pentosus KF340 strain sequentially coated with xylitol, gelatin, and dextrin triple.
도 4는 자일리톨, 콜라겐, 및 덱스트린을 순차적으로 3중 코팅한 락토바실러스 펜토서스 KF340 균주를 주사전자현미경으로 촬영한 사진이다.4 is a photograph taken with a scanning electron microscope of the Lactobacillus pentosus KF340 strain sequentially coated with xylitol, collagen, and dextrin in a triple.
본 발명자들은 유산균의 보관 및 체내에서의 안정성을 증진시킬 수 있는 코팅방법을 개발하기 위하여 예의 연구한 결과, 균주의 저장 및 열안정성, 내산성, 내담즙성, 및 소화효소에 대한 안정성이 증진된 유산균 코팅방법을 개발함으로써 본 발명을 완성하였다.The present inventors have studied diligently to develop a coating method that can enhance the storage and stability of the lactic acid bacteria in the body, and as a result, the storage and thermal stability of the strain, acid resistance, bile resistance, and lactic acid bacteria with enhanced stability to digestive enzymes The present invention has been completed by developing a coating method.
이에, 본 발명은 (a) 유산균에 자일리톨(xylitol)을 첨가하고 균질화 하여 1차 코팅하는 단계; (b) 상기 1차 코팅된 유산균에 젤라틴(gelatin) 또는 콜라겐(collagen)을 첨가하고 균질화 하여 2차 코팅하는 단계; 및 (c) 상기 2차 코팅된 유산균에 덱스트린(dextrin)을 첨가하고 균질화 하여 3차 코팅하는 단계를 포함하는, 안정성이 증진된 유산균의 제조방법을 제공한다.Therefore, the present invention (a) adding xylitol to the lactic acid bacteria and homogenizing the first coating; (b) adding a gelatin or collagen to the first coated lactic acid bacteria and homogenizing the second coating to homogenize; And (c) adding a dextrin (dextrin) to the secondary coated lactic acid bacteria and provides a method of producing a lactic acid bacteria with improved stability, comprising the step of homogeneous tertiary coating.
또한, 본 발명은 (a) 유산균에 자일리톨(xylitol)을 첨가하고 균질화 하여 1차 코팅하는 단계; (b) 상기 1차 코팅된 유산균에 젤라틴(gelatin) 또는 콜라겐(collagen)을 첨가하고 균질화 하여 2차 코팅하는 단계; 및 (c) 상기 2차 코팅된 유산균에 덱스트린(dextrin)을 첨가하고 균질화 하여 3차 코팅하는 단계를 포함하는, 유산균의 안정성 증진 방법을 제공한다.In addition, the present invention (a) adding xylitol to the lactic acid bacteria and homogenizing the first coating; (b) adding a gelatin or collagen to the first coated lactic acid bacteria and homogenizing the second coating to homogenize; And (c) adding a dextrin to the secondary coated lactic acid bacteria and homogenizing the third coating to provide a method for enhancing stability of the lactic acid bacteria.
이하, 본 발명을 단계별로 자세히 설명한다.Hereinafter, the present invention will be described in detail step by step.
상기 제조방법에 따른 유산균 코팅 수행 전에 유산균을 배양하는 과정이 필요하며, 유산균 배양은 이용하는 유산균의 종류에 따라 통상적인 유산균 배양배지 및 배양 조건에서 실시할 수 있으며, 특별히 제한되지 않는다.The process of culturing the lactic acid bacteria before performing the lactic acid bacteria coating according to the production method, the lactic acid bacteria culture can be carried out in conventional lactic acid culture medium and culture conditions according to the type of lactic acid bacteria to be used, and is not particularly limited.
상기 (a) 단계에서, 자일리톨은 증류수에 용해하여 1% 내지 30%, 바람직하게는 1% 내지 15%, 더욱 바람직하게는 3% 내지 7%, 더더욱 바람직하게는 5% 농도일 수 있고, 사용 전 멸균하고 실온에서 냉각한 후 코팅과정에 이용할 수 있다.In step (a), xylitol is dissolved in distilled water and may be in a concentration of 1% to 30%, preferably 1% to 15%, more preferably 3% to 7%, even more preferably 5%, and use. Pre-sterilized, cooled to room temperature and available for coating.
상기 자일리톨은 배양 후 회수한 균체 100 중량부에 대하여 10 중량부 내지 100 중량부, 바람직하게는 50 중량부 내지 100 중량부, 더욱 바람직하게는 회수균체와 동량인 100 중량부를 첨가한 후 균질화하고 상온에서 0.5 내지 3시간, 보다 바람직하게는 1시간 내지 2시간 동안 실온에 정치함으로써 균체를 1차 코팅할 수 있다.The xylitol is added to 10 parts by weight to 100 parts by weight, preferably 50 parts by weight to 100 parts by weight, more preferably 100 parts by weight, which is the same amount as that of recovered cells, and homogenized, and room temperature. The cells can be first coated by standing at room temperature for 0.5 to 3 hours, more preferably 1 hour to 2 hours.
상기 (b) 단계에서, 젤라틴은 증류수에 용해하여 1% 내지 30%, 바람직하게는 1% 내지 15%, 더욱 바람직하게는 4% 내지 7%, 더더욱 바람직하게는 6% 농도일 수 있고, 사용 전 멸균하고 실온에서 냉각한 후 코팅과정에 이용할 수 있다.In the step (b), gelatin may be dissolved in distilled water at a concentration of 1% to 30%, preferably 1% to 15%, more preferably 4% to 7%, even more preferably 6%, and used. Pre-sterilized, cooled to room temperature and available for coating.
상기 젤라틴은 배양 후 회수한 균체 100 중량부에 대하여 0.5 중량부 내지 50 중량부, 바람직하게는 5 중량부 내지 50 중량부, 더욱 바람직하게는 10 중량부 내지 30 중량부를 첨가한 후 균질화하고 상온에서 0.5 내지 3시간, 보다 바람직하게는 1시간 내지 2시간 동안 실온에 정치함으로써 균체를 2차 코팅할 수 있다.The gelatin is added to 0.5 parts by weight to 50 parts by weight, preferably 5 parts by weight to 50 parts by weight, more preferably 10 parts by weight to 30 parts by weight, based on 100 parts by weight of the cells recovered after the culture, and homogenized at room temperature. The cells can be secondary coated by standing at room temperature for 0.5 to 3 hours, more preferably 1 to 2 hours.
상기 (b) 단계에서, 콜라겐은 증류수에 용해하여 1% 내지 30%, 바람직하게는 5% 내지 20%, 더욱 바람직하게는 10% 내지 15%, 더더욱 바람직하게는 12% 농도일 수 있고, 사용 전 멸균하고 실온에서 냉각한 후 코팅과정에 이용할 수 있다.In the step (b), the collagen may be dissolved in distilled water at a concentration of 1% to 30%, preferably 5% to 20%, more preferably 10% to 15%, even more preferably 12%, and used. Pre-sterilized, cooled to room temperature and available for coating.
상기 콜라겐은 배양 후 회수한 균체 100 중량부에 대하여 0.5 중량부 내지 50 중량부, 바람직하게는 5 중량부 내지 50 중량부, 더욱 바람직하게는 10 중량부 내지 30 중량부를 첨가한 후 균질화 하고 상온에서 0.5 내지 3시간, 보다 바람직하게는 1시간 내지 2시간 동안 실온에 정치함으로써 균체를 2차 코팅할 수 있다. The collagen is homogenized after adding 0.5 parts by weight to 50 parts by weight, preferably 5 parts by weight to 50 parts by weight, more preferably 10 parts by weight to 30 parts by weight, based on 100 parts by weight of the cells recovered after the culture. The cells can be secondary coated by standing at room temperature for 0.5 to 3 hours, more preferably 1 to 2 hours.
상기 (c) 단계에서, 덱스트린은 증류수에 용해하여 10% 내지 50%, 바람직하게는 10% 내지 30%, 더욱 바람직하게는 15% 내지 25%, 더더욱 바람직하게는 20% 농도일 수 있고, 사용 전 멸균하고 실온에서 냉각한 후 코팅과정에 이용할 수 있다.In the step (c), the dextrin may be dissolved in distilled water at a concentration of 10% to 50%, preferably 10% to 30%, more preferably 15% to 25%, even more preferably 20%, and used. Pre-sterilized, cooled to room temperature and available for coating.
상기 덱스트린은 배양 후 회수한 균체 100 중량부에 대하여 0.5 중량부 내지 50 중량부, 바람직하게는 5 중량부 내지 50 중량부, 더욱 바람직하게는 10 중량부 내지 30 중량부를 첨가한 후 균질화하고 상온에서 0.5 내지 3시간, 보다 바람직하게는 1시간 내지 2시간 동안 실온에 정치함으로써 균체를 3차 코팅할 수 있다.The dextrin is homogenized after adding 0.5 parts by weight to 50 parts by weight, preferably 5 parts by weight to 50 parts by weight, more preferably 10 parts by weight to 30 parts by weight, based on 100 parts by weight of the cells recovered after the culture. The cells may be tertiary coated by standing at room temperature for 0.5 to 3 hours, more preferably 1 to 2 hours.
본 발명에 따르면, 상기와 같은 유산균 코팅과정 후 코팅된 유산균을 동결건조하는 과정을 포함할 수 있으며, 당업자가 통상적인 방법에 따라 실시할 수 있다.According to the present invention, it may include a process of lyophilizing the coated lactic acid bacteria after the lactic acid bacteria coating process as described above, it can be carried out by those skilled in the art according to a conventional method.
본 발명에 있어서, 상기 안정성은 유산균에 대한 체외에서의 안정성 및 체내에서의 안정성을 모두 포함하는 의미이며, 보다 구체적으로, 유산균에 대하여 저장 및 열에 대한 안정성, 내담즙산, 내산성, 및 소화효소에 대한 안정성, 및 장관조건에서의 안정성을 의미한다.In the present invention, the stability is meant to include both in vitro stability and in vivo stability to lactic acid bacteria, more specifically, storage and heat resistance to lactic acid bacteria, bile acid, acid resistance, and digestive enzymes Stability, and stability in intestinal conditions.
본 발명의 실시예에서는 상기 제조방법으로 락토바실러스 펜토서스 균주를 3중 코팅한 후 코팅 처리하지 않은 경우와 비교하여 다양한 측면에서 균주의 안정성을 평가하였다.In the embodiment of the present invention, the stability of the strain was evaluated in various aspects as compared to the case where the Lactobacillus pentosus strain was not coated after the triple coating by the above production method.
본 발명의 일실시예에서는, 저장안정성 증진여부를 평가하게 위해 상기 유산균 샘플들을 각각 4, 25, 및 40℃ 조건에서 4주 동안 저장하면서 2주 간격으로 생균수 및 생존율을 측정하였다. 그 결과, 저장 온도가 높아질수록 균체의 감소 비율이 증가하는데, 코팅 처리를 하지 않은 경우와 비교하여 3중 코팅한 유산균의 생존율이 크게 증가하는 것을 확인하였다(실시예 3 참조).In one embodiment of the present invention, the viable cell count and viability were measured at two-week intervals while storing the lactic acid bacteria samples for 4 weeks at 4, 25, and 40 ° C. conditions to evaluate storage stability enhancement. As a result, as the storage temperature increases, the rate of decrease of the cells increases, and it was confirmed that the survival rate of the tri-coated lactic acid bacteria was significantly increased as compared with the case without the coating treatment (see Example 3).
본 발명의 다른 실시예에서는, 유산균의 내산성을 평가하기 위해 상기 유산균 샘플들에 대해 각각 pH 2.0 및 2.5의 인공위액을 처리하고 30분, 60분, 및 120분 동안 반응시킨 후 생균수 및 생존율을 측정하였다. 그 결과 코팅 처리를 하지 않은 경우에 비하여 본 발명에 따른 3중 코팅한 샘플에서 높은 생존율을 보이는 것을 알 수 있었다(실시예 4 참조).In another embodiment of the present invention, in order to evaluate the acid resistance of the lactic acid bacteria, the lactic acid bacteria samples were treated with artificial gastric juice of pH 2.0 and 2.5, respectively, and reacted for 30 minutes, 60 minutes, and 120 minutes, and then the viable cell count and survival rate. Measured. As a result, it was found that the survival rate was higher in the triple coated sample according to the present invention compared to the case where the coating was not performed (see Example 4).
본 발명의 또 다른 실시예에서는, 유산균의 내담즙성을 평가하기 위해 상기 유산균 샘플들에 대해 각각 0.3% 및 2.0%의 담즙용액을 처리하고 30분, 60분, 및 120분 동안 반응시킨 후 생균수 및 생존율을 측정한 결과, 코팅 처리를 하지 않은 경우에 비해 3중 코팅 처리한 유산균에서 상대적으로 내담즙성이 크게 증가하는 것을 관찰하였다(실시예 5 참조).In another embodiment of the present invention, to evaluate the bile resistance of the lactic acid bacteria to the lactic acid bacteria samples treated with 0.3% and 2.0% bile solution, respectively, and reacted for 30 minutes, 60 minutes, and 120 minutes As a result of measuring the number and survival rate, it was observed that the bile resistance significantly increased in the tri-coated lactic acid bacteria compared with the case without the coating treatment (see Example 5).
본 발명의 또 다른 실시예에서는, 유산균의 소화효소에 대한 안정성을 평가하기 위해 상기 유산균 샘플들에 대해 0.2% 판크레아틴 및 100 unit/mL의 알파-아밀라아제를 각각 처리하고 30분, 60분, 및 120분 동안 반응시킨 후 생균수 및 생존율을 측정하였다. 그 결과, 본 실시예에서 이용한 락토바실러스 펜토서스 균주 자체의 높은 소화효소 안정성을 확인 할 수 있었고, 본 발명에 따른 3중 코팅 처리에 의해 상기 유산균의 소화효소에 대한 안정성이 보다 증진되는 것을 확인하였다(실시예 6 참조).In another embodiment of the present invention, the lactic acid bacteria were treated with 0.2% pancreatin and 100 unit / mL of alpha-amylase, respectively, for 30 minutes, 60 minutes, and to evaluate the stability of the lactic acid bacteria for digestive enzymes. After reacting for 120 minutes, viable cell count and viability were measured. As a result, it was possible to confirm the high digestive enzyme stability of the Lactobacillus pentosus strain itself used in this example, it was confirmed that the stability of the digestive enzymes of the lactic acid bacteria by the triple coating treatment according to the present invention is more enhanced. (See Example 6).
본 발명의 또 다른 실시예에서는, 유산균의 열에 대한 안정성을 평가하기 위해 상기 유산균 샘플들에 각각 40℃, 50℃, 및 70℃로 온도를 맞춘 멸균 식염수를 가하고 항온수조 내에서 10분 및 30분 동안 온도를 유지시킨 후 생균수 및 생존율을 측정하였다. 그 결과, 코팅 처리하지 않은 샘플에 비하여 3중 코팅 처리한 유산균의 생존율이 높게 측정되었다(실시예 7 참조).In another embodiment of the present invention, to evaluate the heat stability of the lactic acid bacteria to the lactic acid bacteria samples were added sterilized saline at a temperature of 40 ℃, 50 ℃, and 70 ℃ respectively and 10 minutes and 30 minutes in a constant temperature bath The viable cell count and viability were measured after maintaining the temperature for a while. As a result, the survival rate of the tri-coated lactic acid bacteria was higher than that of the non-coated sample (see Example 7).
상기 실시예 결과들을 통해 본 발명에 따른 3중 코팅방법은 코팅 처리하지 않은 유산균에 비하여 보관온도에 따른 저장안정성, 내산성, 내담즙성, 소화효소에 대한 안정성 및 열안정성을 전반적으로 증진시키는 것을 알 수 있었다.Through the results of the above examples, it is found that the triple coating method according to the present invention generally improves the storage stability, acid resistance, bile resistance, stability against digestive enzymes, and thermal stability according to storage temperature, compared to the non-coated lactic acid bacteria. Could.
이에, 본 발명은 상기 제조방법으로 제조된, 3중 코팅된 유산균을 제공한다.Thus, the present invention provides a tri-coated lactic acid bacteria prepared by the above method.
본 발명에 있어서, 상기 유산균은 락토바실러스(Lactobacillus sp .) 속, 비피도박테리움(Bifidobacterium sp .) 속, 스트렙토코커스(Streptococcus sp .) 속, 락토코커스(Lactococcus sp .) 속, 엔테로코커스(Enterococcus sp .) 속, 페디오코커스(Pediococcus sp .) 속, 류코노스톡(Leuconostoc sp .) 속, 및 비셀라(Weissella sp.) 속으로 이루어진 군에서 선택되는 하나 이상의 균주일 수 있고, 보다 바람직하게는 락토바실러스 펜토서스(Lactobacillus pentosus)일 수 있으며, 더욱 바람직하게는 락토바실러스 펜토서스 KF340(수탁번호 KCCM 11675P)일 수 있다.In the present invention, the lactic acid bacteria are Lactobacillus bacteria (Lactobacillus sp.) Genus, Bifidobacterium (Bifidobacterium sp.), A Streptococcus (Streptococcus sp.) Genus Lactococcus (Lactococcus sp.) Genus Enterococcus (Enterococcus sp . ), Pediococcus sp . , Genus Leuconostoc sp . ), And Weissella sp. Genus may be one or more strains selected from the group consisting of, more preferably Lactobacillus pentosus ( Lactobacillus pentosus ), more preferably Lactobacillus pentosus KF340 (Accession number KCCM 11675P).
본 발명은 다양한 변환을 가할 수 있고 여러 가지 실시예를 가질 수 있는 바, 특정 실시예들을 도면에 예시하고 상세한 설명에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 실시 형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술 범위에 포함되는 모든 변환, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 발명을 설명함에 있어서 관련된 공지 기술에 대한 구체적인 설명이 본 발명의 요지를 흐릴 수 있다고 판단되는 경우 그 상세한 설명을 생략한다.As the invention allows for various changes and numerous embodiments, particular embodiments will be illustrated in the drawings and described in detail in the written description. However, this is not intended to limit the present invention to specific embodiments, it should be understood to include all transformations, equivalents, and substitutes included in the spirit and scope of the present invention. In the following description of the present invention, if it is determined that the detailed description of the related known technology may obscure the gist of the present invention, the detailed description thereof will be omitted.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예를 제시한다. 그러나 하기의 실시예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 하기 실시예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples are provided to aid in understanding the present invention. However, the following examples are merely provided to more easily understand the present invention, and the contents of the present invention are not limited by the following examples.
[[ 실시예Example ]]
실시예Example 1. One. 락토바실러스Lactobacillus 펜토서스Pentosus KF340 균주의 배양 Culture of KF340 Strain
락토바실러스 펜토서스 KF340 균주는 360 L의 modified-MRS 배지를 이용하여 32℃, pH 6.0 조건에서 12±3 시간 동안 교반하며 배양하였다. 배양된 락토바실러스 펜토서스 KF340 균체는 원심분리기를 이용하여 분리하였으며, 이 공정을 통해 5.2 Kg의 균체를 회수하였다.Lactobacillus pentosus KF340 strain was incubated with stirring for 12 ± 3 hours at 32 ℃, pH 6.0 conditions using 360 L modified-MRS medium. The cultured Lactobacillus pentosus KF340 cells were separated using a centrifuge, and 5.2 Kg of cells were recovered through this process.
실시예Example 2. 2. 락토바실러스Lactobacillus 펜토서스Pentosus KF340 균주의 KF340 strain 3중Triple 코팅 및 동결건조 Coating and Lyophilization
상기 실시예 1의 방법에 따라 배양한 락토바실러스 펜토서스 KF340 균주에 대하여 균주의 안정성을 증진시키기 위해 3중 코팅방법을 이용하여 균주를 코팅한 후 다양한 방법으로 안정성 증진여부를 평가하고자 하였다. 실험군 1은 자일리톨, 젤라틴, 및 덱스트린을 이용한 3중 코팅 균주이고, 실험군 2는 자일리톨, 콜라겐, 및 덱스트린을 이용한 3중 코팅 균주이며, 대조군은 코팅 처리하지 않은 균주이다.In order to improve the stability of the Lactobacillus pentosus KF340 strain cultured in accordance with the method of Example 1 to coat the strain using a triple coating method to evaluate the stability enhancement by various methods.
구체적인 본 발명에 따른 3중 코팅원료 조성 및 대조군 조성을 하기 표 1에 나타내었다.Specific triple coating material composition and control composition according to the present invention is shown in Table 1 below.
상기 조성의 3중 코팅에 따른 락토바실러스 펜토서스 KF340의 안정성 증진 효과를 평가하기 위해, 실험군 1은 5%의 자일리톨, 6%의 젤라틴, 및 20%의 덱스트린 농도가 되도록 각 원료를 증류수에 용해하고 121℃에서 15분 동안 멸균한 후 실온에서 냉각시켰다. 다음으로 회수균체에 동량의 5% 자일리톨 수용액을 첨가하고 균체를 균질화 한 후 1시간 동안 정치하여 1차 코팅하였다. 1차 코팅된 균체에 6% 젤라틴 수용액을 회수균체의 25%가 되도록 첨가하고 균질화한 후 1시간 동안 정치하여 2차 코팅한 후, 20% 덱스트린 수용액을 회수균체의 25%가 되도록 첨가하고 균체를 균질화 한 후 1시간 동안 정치하여 3차 코팅을 실시하였다. 실험군 2는 5%의 자일리톨, 12%의 콜라겐, 및 20%의 덱스트린 농도가 되도록 각 원료를 증류수에 용해하고 121℃에서 15분 동안 멸균한 후 실온에서 냉각시켰다. 다음으로 회수균체에 동량의 5% 자일리톨 수용액을 첨가하고 균체를 균질화 한 후 1시간 동안 정치하여 1차 코팅하였다. 1차 코팅된 균체에 12% 콜라겐 수용액을 회수균체의 25%가 되도록 첨가하고 균질화한 후 1시간 동안 정치하여 2차 코팅한 후, 20% 덱스트린 수용액을 회수균체의 25%가 되도록 첨가하고 균체를 균질화 한 후 1시간 동안 정치하여 3차 코팅을 실시하였다. 이때, 대조군(3번 샘플)으로는 아무 원료도 처리하지 않음으로써 코팅 처리를 하지 않은 동일 균체를 이용하였다.In order to evaluate the stability enhancing effect of the Lactobacillus pentosus KF340 according to the triple coating of the composition,
상기 원료들을 처리하여 3중 코팅하거나 코팅 처리하지 않은 균체들은 하기 조건에 따라 약 66시간 동안 동결건조 하였다. 보다 구체적으로 -38℃에서 5시간 이상 유지하여 예비동결 하였고, -38℃에서 10℃의 온도로 동결건조를 실시한 후 최종 25℃에서 종료한 후 유지하였다. 상기 방법에 따라 3중 코팅 및 동결건조한 락토바실러스 펜토서스 KF340의 최종 원료 사진은 도 1(실험군 1) 및 도 2(실험군 2)에 나타내었다.Cells treated with the above materials were triple-coated or uncoated cells were lyophilized for about 66 hours under the following conditions. More specifically, pre-freezing was maintained at −38 ° C. for at least 5 hours, and lyophilization was performed at −38 ° C. and at 10 ° C., followed by final termination at 25 ° C. The final raw material photograph of Lactobacillus pentosus KF340 triple-coated and lyophilized according to the above method is shown in FIGS. 1 (Experimental Group 1) and 2 (Experimental Group 2).
이후 상기 샘플들을 대상으로 락토바실러스 펜토서스 KF340 균주의 안정성 증진여부를 다양한 측면에서 평가하였다. Then, the stability of the Lactobacillus pentosus KF340 strain in the samples was evaluated in various aspects.
실시예Example 3. 3. 3중Triple 코팅한 Coated 락토바실러스Lactobacillus 펜토서스Pentosus KF340 균주의 저장안정성 평가 Storage Stability Evaluation of KF340 Strain
본 발명에 따른 원료로 3중 코팅한 락토바실러스 펜토서스 KF340의 저장안정성을 평가하기 위해, 상기 표 1의 샘플들을 실시예 2의 방법에 따라 준비한 후 각각 4, 25, 및 40℃ 조건에서 4주 동안 저장하면서 2주 간격으로 생균수를 측정하였다. 생균수를 측정하기 위해 각 보관온도에서 저장한 균체들을 멸균 식염수로 현탁한 다음, MRS(Difco) 고체 배지에 희석배율에 따라 분주 및 도말한 후 37℃에서 48시간 동안 배양하여 콜로니 숫자를 측정하였다. 이때 생존율 (%)은 [(4주차의 Log 지수값/0주차의 Log 지수값) X 100]으로 나타내었다.In order to evaluate the storage stability of the three-coated Lactobacillus pentosus KF340 with the raw material according to the present invention, the samples of Table 1 were prepared according to the method of Example 2, and then 4 weeks at 4, 25, and 40 ° C., respectively. The viable cell counts were measured at two week intervals during storage. In order to measure the number of viable cells, the cells stored at each storage temperature were suspended in sterile saline solution, aliquoted and smeared according to dilution ratio in MRS (Difco) solid medium, and then cultured for 48 hours at 37 ° C. to measure colony numbers. . The survival rate (%) is expressed as [(Log index value at Week 4 / Log index value at Week 0) X 100].
상기 샘플들을 각각 4, 25, 및 40℃에서 보관한 결과, 하기 표 2 내지 4에 각각 나타낸 바와 같이, 코팅 처리를 하지 않은 대조군은 모든 온도조건에서 3중 코팅한 실험군 1 및 2의 균체에 비해 낮은 생존율을 나타내었다. 또한, 보관 온도가 높아질수록 균체의 감소비율이 증가하는 경향을 보였는데, 이는 기존 보고들과 유사한 결과이며, 보관온도가 높아질수록 아무것도 처리하지 않은 대조군 비해 실험군의 생존율이 크게 증가했다는 점에서 본 발명에 따른 3중 코팅 공정이 상기 균주의 저장안정성을 크게 향상시킴을 확인할 수 있었다.As a result of storing the samples at 4, 25, and 40 ° C., respectively, as shown in Tables 2 to 4, the control group without coating treatment was compared with the cells of
실시예Example 4. 4. 3중Triple 코팅한 Coated 락토바실러스Lactobacillus 펜토서스Pentosus KF340 균주의 KF340 strain 내산성Acid resistance 평가 evaluation
본 발명에 따른 원료로 3중 코팅한 락토바실러스 펜토서스 KF340의 내산성을 평가하기 위해, 상기 표 1의 샘플들을 실시예 2의 방법에 따라 준비한 후 각각 pH 2.0 및 2.5의 인공위액을 가하여 30분, 60분 및 120분 동안 반응시킨 뒤 멸균 식염수로 10배씩 희석하여 MRS(Difco) 고체 배지에 희석배율에 따라 분주 및 도말하였다. 이후 37℃에서 48시간 동안 배양하여 콜로니 숫자를 측정하였으며, 이때 생존율 (%)은 [(인공위액 노출 후 Log 지수값/초기 Log 지수값) X 100]으로 나타내었다.In order to evaluate the acid resistance of the three-coated lactobacillus pentosus KF340 with the raw material according to the present invention, the samples of Table 1 were prepared according to the method of Example 2 and then added with artificial gastric juice of pH 2.0 and 2.5, respectively, for 30 minutes, After reacting for 60 minutes and 120 minutes, the solution was diluted 10-fold with sterile saline solution and dispensed and plated according to the dilution ratio in MRS (Difco) solid medium. Thereafter, the colonies were measured by incubating at 37 ° C. for 48 hours, and the survival rate (%) was expressed as [(Log index value after initial gastric fluid exposure / initial Log index value) × 100].
그 결과, 하기 표 5 및 표 6에 각각 나타낸 바와 같이, 인공위액(pH 용액)에 노출된 시간이 증가함에 따라 균체의 생존율이 감소하는 경향을 보였고, pH 2.0 및 pH 2.5 조건에서 모두 코팅 처리를 하지 않은 대조군에 비하여 3중 코팅한 실험군 1 및 2에서 높은 생존율을 나타내었다. 또한, pH 2.5 조건에서는 98% 이상, pH 2.0의 산성 환경에서도 약 95% 이상의 생존율을 유지하는 것을 볼 때 아무것도 처리하지 않은 경우에 비해 3중 코팅 방법이 상대적으로 내산성을 크게 증가 시킨다는 것을 확인하였다.As a result, as shown in Table 5 and Table 6, the survival rate of the cells showed a tendency to decrease as the time of exposure to gastric juice (pH solution) increased, and coating treatment was performed at both pH 2.0 and pH 2.5 conditions. Compared with the control group did not show a high survival rate in the three-coated
실시예Example 5. 5. 3중Triple 코팅한 Coated 락토바실러스Lactobacillus 펜토서스Pentosus KF340 균주의 KF340 strain 내담즙성Bile resistance 평가 evaluation
본 발명에 따른 원료로 3중 코팅한 락토바실러스 펜토서스 KF340의 내담즙성을 평가하기 위해, 상기 표 1의 샘플들을 실시예 2의 방법에 따라 준비한 후 담즙 용액(Bile extract 0.3%, 2.0%)을 가하여 30분, 60분 및 120분 동안 반응시킨 뒤 멸균 식염수로 10배씩 희석하여 MRS(Difco) 고체 배지에 희석배율에 따라 분주 및 도말하였다. 37℃에서 48시간 동안 배양하여 콜로니 숫자를 측정한 후, 이때 생존율 (%)은 [(담즙산 노출 후 Log 지수값/초기 Log 지수값) X 100]으로 나타내었다.In order to evaluate the bile resistance of Lactobacillus pentosus KF340 three-coated with the raw material according to the present invention, the samples of Table 1 were prepared according to the method of Example 2 and then bile solution (Bile extract 0.3%, 2.0%) The reaction was carried out for 30 minutes, 60 minutes and 120 minutes, and then diluted 10-fold with sterile saline, and then dispensed and plated according to the dilution ratio in MRS (Difco) solid medium. After culturing at 37 ° C. for 48 hours to determine colony numbers, the survival rate (%) was expressed as [(Log index value after initial bile acid exposure / initial Log index value) × 100].
0.3% 및 2.0%의 담즙 용액과 반응시킨 결과, 하기 표 7 및 8에 각각 나타낸 바와 같이, 담즙 용액(Bile extract)의 농도와 노출시간이 증가함에 따라 균체들의 생존율이 감소하는 경향을 보였고, 코팅 처리를 하지 않은 대조군과 비교할 때 3중 코팅한 실험군 1 및 2에서 비교적 높은 생존율을 보였다. 상기 결과를 통해 아무것도 처리하지 않은 경우에 비해 3중 코팅 방법이 상대적으로 내담즙성을 크게 증가 시킨다는 것을 알 수 있었다.As a result of the reaction with 0.3% and 2.0% bile solution, as shown in Tables 7 and 8, the viability of the cells showed a tendency to decrease as the concentration and exposure time of the bile solution increased.
실시예Example 6. 6. 3중Triple 코팅한 Coated 락토바실러스Lactobacillus 펜토서스Pentosus KF340 균주의 소화효소에 대한 안정성 평가 Evaluation of Stability of Digestive Enzymes of KF340 Strains
본 발명에 따른 원료로 3중 코팅한 락토바실러스 펜토서스 KF340의 소화효소에 대한 안정성을 평가하기 위해, 상기 표 1의 샘플들을 실시예 2의 방법에 따라 준비한 후 소화효소 용액 즉, 0.2% 판크레아틴(pancreatin) 및 100 unit/mL의 알파-아밀라아제(α-amylase)를 각각 첨가하여 30분, 60분, 및 120분 동안 반응시킨 뒤 멸균 식염수로 10배씩 희석하여 MRS(Difco) 고체 배지에 희석배율에 따라 분주 및 도말하였다. 37℃에서 48시간 동안 배양한 후 콜로니 숫자를 측정하였으며, 이때 생존율 (%)은 [(소화효소 용액 노출 후 Log 지수값/초기 Log 지수값) X 100]으로 나타내었다.In order to evaluate the stability of the three-coated lactobacillus pentosus KF340 with the raw material according to the invention for the digestive enzymes, the samples of Table 1 were prepared according to the method of Example 2 after digestion enzyme solution, that is, 0.2% pancreatin (pancreatin) and 100 unit / mL of alpha-amylase were added, respectively, and reacted for 30 minutes, 60 minutes, and 120 minutes, and then diluted 10-fold with sterile saline solution to dilute the MRS (Difco) solid medium. Dispensed and smeared accordingly. Colonies were measured after incubation at 37 ° C. for 48 hours. The survival rate (%) was expressed as [(Log index value / initial Log index value after digestive enzyme solution exposure) × 100].
상기 샘플들을 각각 판크레아틴 및 아밀라아제와 반응시킨 결과, 하기 표 9 및 표 10에 나타낸 바와 같이, 1번 내지 3번 샘플에서 모두 균체들의 생존율이 높게 나타났고, 코팅 처리를 하지 않은 대조군의 경우에도 95% 이상의 생존율이 확인되어 락토바실러스 펜토서스 KF340 균주 자체가 판크레아틴과 아밀라아제에 대한 저항성이 매우 높은 것을 알 수 있었다. 그러나 코팅을 하지 않은 대조군 보다는 3중 코팅한 실험군 1 및 2의 생존율이 약 100%로 유지된다는 점에서 3중 코팅 처리가 락토바실러스 펜토서스 KF340 균주의 소화효소에 대한 안정성을 보다 향상시키는 것을 알 수 있었다.As a result of reacting the samples with pancreatin and amylase, respectively, as shown in Tables 9 and 10, the survival rates of the cells were high in
실시예Example 7. 7. 3중Triple 코팅한 Coated 락토바실러스Lactobacillus 펜토서스Pentosus KF340 균주의 KF340 strain 열안정성Thermal stability 평가 evaluation
본 발명에 따른 원료로 3중 코팅한 락토바실러스 펜토서스 KF340의 열에 대한 안정성을 평가하기 위해, 상기 표 1의 샘플들을 실시예 2의 방법에 따라 준비한 후 40℃, 50℃, 및 70℃로 온도를 맞춘 멸균 식염수를 각 샘플에 가하여 항온수조 내에서 10분 및 30분 동안 동일한 온도로 유지시킨 후 멸균 식염수로 10배씩 희석하여 MRS(Difco) 고체 배지에 희석배율에 따라 분주 및 도말하였다. 37℃에서 48시간 동안 배양한 후 콜로니 숫자를 측정하였으며, 이때 생존율 (%)은 [(열처리 후 Log 지수값/초기 Log 지수값) X 100]으로 나타내었다. In order to evaluate the heat stability of the three-coated lactobacillus pentosus KF340 with the raw material according to the invention, the samples of Table 1 were prepared according to the method of Example 2 and then the temperature at 40 ℃, 50 ℃, and 70 ℃ Sterile saline solution was added to each sample and maintained at the same temperature for 10 minutes and 30 minutes in a constant temperature bath, and then diluted 10 times with sterile saline solution and dispensed and plated according to the dilution ratio in MRS (Difco) solid medium. After 48 hours of incubation at 37 ℃ colony number was measured, the survival rate (%) is expressed as [(Log index value / initial Log index value after heat treatment) X 100].
각각 40℃, 50℃, 및 70℃ 조건에서의 열안정성 평가 결과, 하기 표 11 내지 표 13에 나타낸 바와 같이, 40℃ 조건에서는 코팅 처리를 하지 않은 대조군에서도 96% 이상, 3중 코팅한 실험군 1 및 2의 생존율은 약 100%로 유지된다는 점에서 40℃ 조건에서 락토바실러스 펜토서스 KF340의 높은 열안정성을 확인하였다. 50℃ 조건에서는 코팅을 하지 않은 대조군이 약 85%의 생존율을 유지하는데 비해 3중 코팅한 실험군 1 및 2의 경우 생존율을 90%이상까지 향상시킨다는 점에서 3중 코팅 처리가 LPKF340 균주의 열에 대한 안정성을 보다 향상시키는 것을 알 수 있었다. 코팅처리에 따른 열안정성 차이는 70℃ 고온 조건에서 보다 두드러지게 나타나 코팅 처리 하지 않은 대조군이 30분의 열처리 과정을 거친 후 생균이 확인되지 않은 것과 달리 3중 코팅한 실험군 1은 균체 생존율을 30% 이상까지 크게 향상시키고 3중 코팅한 실험군 2는 균체 생존율을 20% 이상까지 향상시킨다는 점에서 큰 의의를 갖는다. 따라서 이전의 결과들을 종합하여 볼 때 락토바실러스 펜토서스 KF340의 3중 코팅 샘플은 외부 환경으로부터 균주를 보호함으로써 보관온도에 따른 저장안정성, 내산성, 내담즙성, 소화효소에 대한 안정성 및 열안정성을 전반적으로 향상시키는 것을 알 수 있었다.As a result of evaluation of thermal stability at 40 ° C., 50 ° C., and 70 ° C., respectively, as shown in Tables 11 to 13 below, at 40 ° C., at least 96% of the control group not coated with the test group was coated in
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가지는 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야만 한다.The above description of the present invention is intended for illustration, and those of ordinary skill in the art can understand that the present invention can be easily modified in other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive.
본 발명은 자일리톨; 젤라틴 또는 콜라겐; 및 덱스트린을 이용하여 순차적으로 유산균을 3중 코팅함으로써 종래 코팅 처리하지 않은 유산균보다 보관온도 및 열에 대한 안정성, 내산성, 내담즙성, 및 소화효소에 대한 안정성이 증진되는 것을 실험적으로 확인하였다. 이에, 본 발명은 3중 코팅으로 안정성이 증진된 유산균은 사멸하지 않고 위장관을 통과하여 장내에서 본래의 생리활성 기능을 유지할 수 있는바, 발효유, 발효식품, 기능성 식품, 일반식품, 화장품, 및 의약품 등의 관련 산업에서 유용하게 이용될 것으로 기대된다.The present invention is xylitol; Gelatin or collagen; And by sequentially coating the lactic acid bacteria with dextrin in triplicate, it was experimentally confirmed that the stability to storage temperature and heat, acid resistance, bile resistance, and digestive enzymes were improved more than lactic acid bacteria which were not conventionally coated. Thus, the present invention can be maintained in the intestinal physiological activity through the gastrointestinal tract without killing the lactic acid bacteria enhanced stability by triple coating, fermented milk, fermented foods, functional foods, general foods, cosmetics, and pharmaceuticals It is expected to be usefully used in related industries.
Claims (14)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2016-0172787 | 2016-12-16 | ||
| KR10-2016-0172558 | 2016-12-16 | ||
| KR20160172787 | 2016-12-16 | ||
| KR20160172558 | 2016-12-16 | ||
| KR1020170172396A KR102004204B1 (en) | 2016-12-16 | 2017-12-14 | lactic acid bacteria improved stability and preparing method thereof |
| KR10-2017-0172396 | 2017-12-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2018111023A1 true WO2018111023A1 (en) | 2018-06-21 |
Family
ID=62559521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2017/014806 Ceased WO2018111023A1 (en) | 2016-12-16 | 2017-12-15 | Lactic acid bacteria having increased stability, and method for producing same |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2018111023A1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100387245B1 (en) * | 1997-10-17 | 2003-08-19 | 일양약품주식회사 | Enteric coated microgranules for stabilizing lactic acid bacteria |
| US7229818B2 (en) * | 2003-01-14 | 2007-06-12 | Randolph Stanley Porubcan | Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life |
| KR20070104140A (en) * | 2006-04-21 | 2007-10-25 | (주)케비젠 | Preparation method of lactic acid multi-microcapsules, microcapsules manufactured by the method and products containing the same |
| KR20090082035A (en) * | 2008-01-25 | 2009-07-29 | 정명준 | Method for producing tri-coated lactic acid bacteria and nano-particle coating method, tri-coated lactic acid bacteria prepared by the method and products comprising the same |
| US20150359894A1 (en) * | 2006-09-27 | 2015-12-17 | Little Calumet Holdings, Llc | Probiotic oral dosage forms |
-
2017
- 2017-12-15 WO PCT/KR2017/014806 patent/WO2018111023A1/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100387245B1 (en) * | 1997-10-17 | 2003-08-19 | 일양약품주식회사 | Enteric coated microgranules for stabilizing lactic acid bacteria |
| US7229818B2 (en) * | 2003-01-14 | 2007-06-12 | Randolph Stanley Porubcan | Formulations to increase in vivo survival of probiotic bacteria and extend their shelf-life |
| KR20070104140A (en) * | 2006-04-21 | 2007-10-25 | (주)케비젠 | Preparation method of lactic acid multi-microcapsules, microcapsules manufactured by the method and products containing the same |
| US20150359894A1 (en) * | 2006-09-27 | 2015-12-17 | Little Calumet Holdings, Llc | Probiotic oral dosage forms |
| KR20090082035A (en) * | 2008-01-25 | 2009-07-29 | 정명준 | Method for producing tri-coated lactic acid bacteria and nano-particle coating method, tri-coated lactic acid bacteria prepared by the method and products comprising the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0555618B1 (en) | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria | |
| JP3993168B2 (en) | Compositions comprising Lactobacillus pentosus strains and their use | |
| KR102048690B1 (en) | lactic acid bacteria improved stability and preparing method thereof | |
| US10597740B2 (en) | Bifidobacterium longum CBT BG7 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same | |
| WO2012060579A2 (en) | Dead lactobacillus biomass for antimicrobial use and a production method therefor | |
| WO2016200048A1 (en) | Method for increasing survival rate, storage stability, acid resistance or bile resistance of lactic acid bacterium | |
| KR20010071416A (en) | Lactic acid bacterium-containing compositions, drugs and foods | |
| CN115029260B (en) | A kind of Lactobacillus gasseri with anti-inflammation and anti-oxidation properties and its application | |
| CN112625979B (en) | A kind of Lactobacillus casei against Helicobacter pylori and application thereof | |
| US20190298784A1 (en) | Bifidobacterium breve cbt br3 strain for promotion of growth and nutraceutical composition for promotion of growth containing the same | |
| CN113151113B (en) | A strain of Clostridium butyricum with strong antibacterial ability and its application | |
| RU2152993C1 (en) | Strain of bifidobacterium bifidum vkpm ac-1578 used for preparing bacterial preparation and foodstuff product | |
| AU2002348340B2 (en) | Probiotic compositions | |
| US20190343857A1 (en) | Prebiotic composition containing butyryl-fructooligosaccharides | |
| CN113122466B (en) | Enterococcus faecalis and application thereof | |
| AU2002348340A1 (en) | Probiotic compositions | |
| WO2022149869A1 (en) | Composition for activating probiotics through inhibition of harmful bacteria | |
| CN118028148A (en) | Enterococcus faecalis MB2 and application thereof in preparation of anti-inflammatory and hypoglycemic foods and medicines | |
| CN114806953B (en) | Lactobacillus gasseri with effect of improving type 1 diabetes | |
| SI24570A (en) | New strains of the genus Lactobacillus and use thereof | |
| WO2017222142A1 (en) | Bacillus licheniformis strain ny1505 for mass producing α-glucosidase inhibitor | |
| KR102004204B1 (en) | lactic acid bacteria improved stability and preparing method thereof | |
| WO2017026635A1 (en) | Novel lactobacillus sp. microorganisms, and composition for animal feed comprising same | |
| KR19990035280A (en) | Lactobacillus ashdophyllus KY 2104 and its uses | |
| WO2018111023A1 (en) | Lactic acid bacteria having increased stability, and method for producing same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17880996 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 17880996 Country of ref document: EP Kind code of ref document: A1 |